日本語View as Markdown

Hydrogen: A Potential New Adjuvant Therapy for COVID-19 Patients.

COVID-19患者における水素の補助的活用の可能性に関する考察

review inhalation not assessed

Abstract

Molecular hydrogen exhibits multiple biological properties including antioxidant activity, anti-inflammatory effects, hormone regulation, and resistance to apoptosis. This review examines the possibility that H2 administration during the early phase of SARS-CoV-2 infection could help suppress excessive cytokine release and associated lung damage, facilitate clearance of viscous secretions, and lower the rate of disease progression to severe stages. The authors note that definitive conclusions regarding efficacy and safety will require confirmation through large-scale clinical investigations.

Mechanism

H2 may mitigate SARS-CoV-2-induced lung injury by scavenging reactive oxygen species and suppressing the excessive cytokine cascade, while also facilitating sputum clearance through its anti-inflammatory properties.

Bibliographic

Authors
Yang F, Yue R, Luo X, Liu R, Huang X
Journal
Front Pharmacol
Year
2020
PMID
33178011
DOI
10.3389/fphar.2020.543718
PMC
PMC7593510

Tags

Disease:COVID-19 Delivery:吸入投与 Mechanism:アポトーシス抑制 免疫調節 炎症抑制 酸化ストレス 活性酸素種

Delivery context

For inhalation applications of molecular hydrogen, the lower flammability limit (LFL) deserves careful handling. The classical 4% figure applies to closed-system mixtures; the practical inhalation-environment threshold is 10%. Even pure-hydrogen output (the UFL 75% paradox) passes through the flammable range at the air–gas boundary. High-concentration (66% / 100%) inhalers are documented in the Japanese Consumer Affairs Agency accident-information database and are not recommended.

Safety notes

For inhalation applications of molecular hydrogen, the lower flammability limit (LFL) deserves careful handling. The classical 4% figure applies to closed-system mixtures; the practical inhalation-environment threshold is 10%. Even pure-hydrogen output (the UFL 75% paradox) passes through the flammable range at the air–gas boundary. High-concentration (66% / 100%) inhalers are documented in the Japanese Consumer Affairs Agency accident-information database and are not recommended.

See also:

Other papers on the same disease / condition

Cite as: H2 Papers — PMID 33178011. https://h2-papers.org/en/papers/33178011
Source: PubMed PMID 33178011